Introduction {#s1}
============

Arrhythmia is a disease featuring the abnormalities of frequency or rhythm of heart excitement caused by abnormal cardiac electrophysiological activities generated by the electrical conduction system of the heart. Symptoms of arrhythmia often include dizziness, breathlessness, and palpitations ([@B3]). The presence of cardiac arrhythmias may at times suggest a specific underlying heart disease or even noncardiac pathological changes. The most common and important cause of cardiac arrhythmias is coronary artery disease ([@B1]). In recent decades, even though plenty of non-chemical therapies have been developed, anti-arrhythmic drug is still the most common treatment. However, the proarrhythmic effect of the anti-arrhythmic drugs has been causing concerns on the safety of the arrhythmic patients.

As a complementary and alternative medicine, Chinese medicine plays an increasing role in the treatment of arrhythmias ([@B9]). Many proprietary Chinese medicines, such as Xin Su Ning capsule ([@B46]; [@B38]; [@B23]; [@B20]; [@B47]), Wenxin Keli ([@B18]; [@B21]), and Shensong Yangxin capsule ([@B36]; [@B24]), have showed clear clinical antiarrhythmic efficacy comparable with the single chemical compound anti-arrhythmic drugs. However, the Chinese-patented antiarrhythmic medicines have rare adverse reactions being recorded.

Based on the theories of traditional Chinese medicine (TCM), a disease can be categorized from four fundamental dimensions, which is consisted of four pairs of relative concepts including yin--yang, exterior--interior, excess--deficiency, and cold--heat ([@B25]; [@B16]). In terms of excess--deficiency categorization, arrhythmia can be divided into two main types of syndromes: excess syndrome and deficient syndrome ([@B6]). Deficiency syndrome is a TCM condition with weakness and lack of energy. Up to present, most of the marketed anti-arrhythmic Chinese medicines have been used to treat deficient syndrome, such as Wenxin Keli ([@B42]) and Shensong Yangxin capsule ([@B13]) for the deficiency of Qi and Yin, Xinbao Wan for the deficiency of Yang ([@B5]; [@B8]), and Tianwang Buxin Wan for the deficiency of Yin ([@B29]). Excess syndrome is a typical TCM syndrome caused by the accumulation of pathological phlegm and dampness in the body. Cardiac arrhythmia with typical clinical manifestation of phlegm-heat heart-disturbance (PHHD) syndrome takes a large proportion of the clinical treatment, and to the best of our knowledge, XSN is the only medicine for treating PHHD arrhythmia ([@B46]).

Xin Su Ning (XSN) is a multi-herbal medicine patented and launched in China since 2005 for treating cardiac ventricular arrhythmia, especially arrhythmias induced by cardiac ischemia and viral myocarditis ([@B47]). XSN is comprised of 11 herbs: *Coptidis Rhizoma* (Huanglian, *Coptis chinensis* Franch.), *Pinelliae Rhizoma* (Banxia, *Pinellia ternata* \[Thunb.\] Makino), Poria (Fuling, *Poria cocos* \[Schw.\] Wolf), *Aurantii Fructus Immaturus* (Zhishi, *Citrus aurantium* L.), *Dichroae Radix* (Changshan, *Dichroa febrifuga* Lour.), *Nelumbinis Plumula* (Lianzixin, *Nelumbo nucifera* Gaertn.), *Sophorae flavescentis Radix* (Kushen, *Sophora flavescens* Ait.), *Artemisiae annuae Herba* (Qinghao, *Artemisia annua* L.), *Ginseng Radix et Rhizoma* (Renshen, *Panax ginseng* C. A. Mey.), *Ophiopogonis Radix* (Maidong, *Ophiopogon japonicus* (L. f) Ker Gawl.), and *Nardostachyos Radix et Rhizoma* (Gancao, *Glycyrrhiza uralensis* Fisch.).

However, the complexity of the chemical composition of multi-herbal TCM formula brings great difficulties to the pharmacological research. Network pharmacology has been one of the approaches to reveal the complex pharmacological mechanisms behind the multitargeting properties by the multicomponent medicines ([@B22]). TCM formulas are well known by the characteristics of multi-herbal/component, which would exert its clinical efficacy through multiple targeting, hence multi-pharmacological actions ([@B19]). However, most of the studies were centered on attributing the edge between component and target and considering the weight values of all the components as the same ([@B33]). A good TCM formula would be formed with the right herbs in an accurate proportion that would produce the best possible clinical efficacy with none or minimal toxicity. Therefore, each herb in a formula would be indispensable in evaluating the clinical efficacy of the formula as well as in a network pharmacological mechanism mapping. Furthermore, in terms of compound formula which consists of multiple herbs, the target spectrum (target distribution of all monomer components) determines the therapeutic range of the formula, and high-weight components may determine the therapeutic direction.

In this study, we tried to introduce a parameter, weight coefficient, to mimic the proportion of all the encompassed components and resort their effects on different targets and pathways. We used the data from multiple bioassay databases, combining with the results of pharmacological assays of high-weight coefficient components; a closer-to-the-fact pharmacological panorama was constructed.

Materials and Methods {#s2}
=====================

XSN Chemical Component Library Building {#s2_1}
---------------------------------------

All of the chemical monomer components in the 11 herbs of XSN were retrieved from the book Chemical Components of Source Plants in Traditional Chinese Medicine ([@B48]) and the database: TCM Systems Pharmacology Database and Analysis Platform (TcmSP™, <http://lsp.nwu.edu.cn/tcmsp.php>) ([@B31]). In addition, four important pharmacology-related properties of the collected components were also obtained from admetSAR ([@B7]; [@B45]), including MW, ALogP, Hbond donor count, and Hbond acceptor count, Rotation bond count, and human oral bioavailability (HOB). The proportion of each herb in XSN formula was retrieved from the patent of XSN ([@B37]), and the contents of the main active components in all the 11 herbs were retrieved from published papers, and all the other components without quantitative data were set to be equal to the lowest quantity value of known components (details see [**Supplement Table 1**](#SM1){ref-type="supplementary-material"}).

Calculation of Weight Coefficients {#s2_2}
----------------------------------

Component weight coefficient:
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*w* ~i,j~ is the weight coefficient of component *j* in herb *i*, and *m~i~* is the weight of herb *i* in XSN formula, *n* is the total count of herbs in XSN, *C~i,j~* is the content of component *j* in herb *i*, and *M~j~* is the molecular weight of component *j*, and *p~j~*(*OB*) is the predicted probability of positive human OB of component *j*.

The weight coefficient is the product of three elements: $\frac{m_{i}}{\sum_{i}^{n}m_{i}}$ is the proportion of each herb in the XSN formula, $\frac{c_{i,j}}{M_{j}}$ represented the molar concentration of each component in 1 gram of raw herb in XSN formula, and *pj(OB)* is the probability of the bioavailability of each component reaching 30% of the total oral administration. Therefore, the coefficient *w~i,j~* is a relative quantity among all the components of the 11 herbs in XSN formula to reflect the proportional relationships of the components existed in the body.

Since the activity of the multiple herbal medicine involved in multiple targeting, and each target was usually bound by multiple components. Weight coefficient of one single target in this paper was represented by the sum of all the weight coefficients of the components interacting with this target. Furthermore, weight coefficient of each pathway was also represented by the sum of all the weight coefficients of all targets in this pathway.

Establishment of the Relationships Between Component-Target and Zheng Target {#s2_3}
----------------------------------------------------------------------------

All the relative targets of each component in the 11 herbs of XSN were retrieved from BindingDB database (<https://www.bindingdb.org/>) as the component-target relationship library of XSN ([@B12]). Since Zheng (TCM syndrome) is represented by the series of characteristics with clinical manifestations and symptoms (hereinafter referred to as TCM symptom), all the 10 TCM symptoms of PHHD arrhythmia referred in the indications of XSN capsule and the standard names of their corresponding modern medicine symptoms (MM symptom) were collected from SymMap database (<https://www.symmap.org/>) ([@B43]). All the target genes relative to each MM symptom above were obtained from the Human Phenotype Ontology Database (<https://hpo.jax.org/app/>) as the target-Zheng relationship library of PHHD arrhythmia.

Network Construction and Analysis {#s2_4}
---------------------------------

Two networks were constructed: the networks of PHHD target and XSN component targets. All the networks were visualized by Cytoscape 3.7.0 (<http://www.cytoscape.org>), which is an open-source project for complex network construction and visualizing and analyzing ([@B32]). Pathway enrichment was carried out using Reactome pathway database (<https://www.reactome.org>) ([@B11]; [@B10]); the pathways with FDR \< 0.05 were kept in the result.

Chemicals and Solutions {#s2_5}
-----------------------

All the chemical agents were purchased from Sigma--Aldrich, and all high-weight coefficient components were obtained from Chengdu Herbpurify Co., Ltd. The intracellular buffer contained (in mM): KCl 120, MgCl~2~ 2, CaCl~2~ 1, Na~2~ATP 3, EGTA 11, HEPES 10, and pH 7.2 corrected with 5M NaOH. The extracellular buffer contained (in mM): NaCl 112, NaH~2~PO~4~•H~2~O 1, KCl 5.4, HEPES 5, NaHCO~3~ 24, glucose 10, MgCl~2~ 1.2, CaCl~2~ 1.8, and pH 7.4 corrected with 5M NaOH. Components experimented in this paper were dissolved in the external buffer, and for the dose--response research, the concentrations of the compounds studied were ranging from 1 to 100 μM in the external buffer solution.

Electrophysiological Research {#s2_6}
-----------------------------

CHL cells stably expressing the α-subunit of human Na~V~1.5 (SCN5A) were used for electrophysiological assays. Patch clamp assays were carried out at room temperature (∼ 22 to 24°C), and the cells were superfused with the extracellular buffer at a rate of 2 ml/min. Patch pipettes were pulled from borosilicate glass (Harvard Apparatus, UK) using a DMZ-Universal Puller (Zeitz-Instruments, Germany); the average pipette resistance was 3--5 MΩ. The control currents were recorded 5 minutes after the whole-cell configuration was achieved using an Axopatch™ 200B Amplifier (Molecular Devices, USA).

Data Analysis {#s2_7}
-------------

Data was analyzed and illustrated using pCLAMP 10.3 software (Axon Instruments, Inc.) and Origin 9.1. For each protocol and condition, at least five cells were tested. Data values are presented as mean ± standard error of the mean (SEM). The difference between the control and the effect of a compound was statistically tested using Student's unpaired t-test. *P* \< 0.05 was deemed to be statistically significant. Where results are not statistically significant, the actual *p*-value is provided.

Results {#s3}
=======

XSN Component Library {#s3_1}
---------------------

Nine hundred sixty-three monomer components from 11 herbs of XSN were collected from Chemical Components of Source Plants in Traditional Chinese Medicine and TCMSP database ([**Supplement Table 1**](#SM1){ref-type="supplementary-material"}). Chemical properties including AlogP, Hbond donor and acceptor count, molecular weight (MW), human OB, and rotatable bond count were calculated by AdmetSar 2.0 as described above, analyzed and shown as [**Figures 1A--F**](#f1){ref-type="fig"} ([**Supplement Table 1**](#SM1){ref-type="supplementary-material"}). The component accounts of each herb were analyzed and shown in [**Figure 1G**](#f1){ref-type="fig"}. The content of monomer components was obtained from published chemical constituent research indexed by PubMed (<https://www.ncbi.nlm.nih.gov/pubmed>) and CNKI (<http://www.cnki.net/>) ([**Supplement Table 1**](#SM1){ref-type="supplementary-material"}). The contents of 47 of 963 components above were quantified in the reports, and the content values were abstracted from the references. The contents of the remaining 916 components were set as the lowest value of the content reported components. The most abundant component berberine was 2.82×10^6^ times that of neohesperidin which was with the lowest content in the 47 reported components. The weight coefficients for all the components were calculated, and top 40 with references were listed and shown in [**Figure 1H**](#f1){ref-type="fig"} with higher weight components.

![Chemical properties statistics of components in the 11 herbs of XSN. **(A)** AlogP, **(B)** Hbond donor count, **(C)** Hbond acceptor count, **(D)** Molecular weight (MW), **(E)** human oral bioavailability, **(F)** rotatable bond count, **(G)** component count of each herb collected in XSN component library, and **(H)** weight coefficient of top 40 weight components in 11 herbs. The different colors means the source herb of components, which is same as **(G)**.](fphar-10-01138-g001){#f1}

XSN Target Spectrum {#s3_2}
-------------------

Two thousand eight hundred thirty-five component-target relationship data were obtained, covering 487 monomer components and 618 targets ([**Supplement Table 2**](#SM2){ref-type="supplementary-material"}). The classification of targets was analyzed using the ChEMBL hierarchical target classification system ([@B4]), and the classification of enzymes were updated according to the ENZYME database ([@B2]). Major and secondary classifications of target spectrum were shown as [**Figure 2**](#f2){ref-type="fig"} ([**Supplement Table 3**](#SM3){ref-type="supplementary-material"}). The proportion of targets were grouped by the means of target count in [**Figure 2**](#f2){ref-type="fig"}, which shows the proportion of different target categories and also shows the differences between statistics by target count and weight coefficient, especially for cytochrome P450, hydrolase, nuclear receptor, enzymes, oxidoreductase, protease, protein kinase, and VGIC (proportion \> 5% and fold change \>3).

![The targeting spectrum of XSN. **(A)** Statistic and major classifications of XSN target spectrum by target count and **(B)** statistic and secondary classifications of XSN target spectrum. The X axis of **(B)** is labeled with targets including family A GPCR, rhodopsin-like GPCRs; family B GPCR, secretin-like GPCRs; family C GPCR, metabotropic glutamate receptor family; LGIC, ligand-gated ion channel; VGIC, voltage-gated ion channel.](fphar-10-01138-g002){#f2}

PHHD-Arrhythmia Target Spectrum {#s3_3}
-------------------------------

Since Zheng (TCM syndrome) is represented by the series of characteristics with clinical manifestations and symptoms (hereinafter referred to as TCM symptom); all the 10 TCM symptoms of PHHD arrhythmia and their relative modern medicine symptoms (MM symptom) were collected: Xin Ji (palpitations), Xiong Men (respiratory distress), Xin Fan (boredom), Yi Jing (panic attack), Kou Gan (xerostomia), Kou Ku (bitter taste in the mouth), Shi Mian (insomnia), Duo Meng (dreaminess), Xuan Yun (vertigo), and Mai Jie Dai (knotted or regularly intermittent pulse) ([**Table 1**](#T1){ref-type="table"}, [**Supplement Table 4**](#SM4){ref-type="supplementary-material"}).

###### 

The relative relationship between TCM symptoms and modern medicine symptom.

  TCM symptom ID   TCM symptoms    MM symptom ID   MM symptoms       UMLS ID    Synonyms                         UMLS ID    HPO ID       Target number
  ---------------- --------------- --------------- ----------------- ---------- -------------------------------- ---------- ------------ ---------------
  SMTS01333        *Xin Ji*        SMMS00282       Palpitations      C0030252                                               HP:0001962   52
  SMTS01384        *Xiong Men*     SMMS00863       Chest Heaviness   C0742339   Respiratory distress             C0013404   HP:0002098   108
  SMTS01324        *Xin Fan*       SMMS00381       Boredom           C0006019                                                            
  SMTS01567        *Yi Jing*       SMMS00119       Panic Attack      C0086769                                               HP:0025269   17
  SMTS00573        *Kou Gan*       SMMS00144       Xerostomia        C0043352                                               HP:0000217   42
  SMTS00580        *Kou Ku*        SMMS00585       Halitosis         C0018520   Abnormality of taste sensation   C4025879   HP:0000223   6
  SMTS00970        *Shi Mian*      SMMS00033       Insomnia          C0917801                                               HP:0100785   12
  SMTS00211        *Duo Meng*      SMMS00738       Nightmares        C0028084                                                            
  SMTS01439        *Xuan Yun*      SMMS00115       Vertigo           C0042571                                               HP:0002321   72
  N/A              *Mai Jie Dai*                                                Irregular heart beat                        0011675      317

TCM, traditional Chinese medicine; MM, modern medicine; UMLS, Unified Medical Language System; HPO, human phenotype ontology.

TCM symptom Kou Ku means bitter taste in the mouth, but not bad breath in the mouth; therefore, the MM symptom halitosis retrieved from SymMap was replaced by another keyword: abnormality of taste sensation. Mai Jie Dai included two types of pulses: Jie Mai is knotted or bound pulse, which is slow, relaxed and stops at irregular intervals. Jie Mai represents an irregular beat or palpitation stemming from the heart. Dai Mai means the pulse is with regularly intermittent abnormality, which also suggests the patients with this pulse have advanced heart disease according to modern medicine. Therefore, an alternative keyword irregular heartbeat was used to represent the TCM symptom Mai Jie Dai.

Five hundred two targets in total for PHHD arrhythmia were collected as PHHD-arrhythmia target spectrum; statistics of target count for each TCM symptom were shown in [**Figure 3**](#f3){ref-type="fig"} ([**Supplement Table 4**](#SM4){ref-type="supplementary-material"}).

![Statistics of target count for each TCM symptom of PHHD arrhythmia.](fphar-10-01138-g003){#f3}

To obtain the pharmacological network of XSN on treating PHHD arrhythmia, 40 targets were obtained in the common set of XSN target spectrum and PHHD-arrhythmia target spectrum ([**Table 2**](#T2){ref-type="table"}). All the components interact with the 40 targets above consist of the panoramagram of the pharmacological mechanism of XSN for treating PHHD arrhythmia.

###### 

The common genes between XSN target spectrum and PHHD-arrhythmia target spectrum.

  Gene_Symbol   TCM_Symptom                         Target_Weight_Coefficient   UniProt_ID   ChEMBL_ID       Target_Name                                                                Classification_1       Classification_2
  ------------- ----------------------------------- --------------------------- ------------ --------------- -------------------------------------------------------------------------- ---------------------- -----------------------------
  CALM1         Maijiedai, Xuanyun                  790.2976034                 P0DP23       CHEMBL6093      Calmodulin                                                                 Other                  Unclassified protein
  KCNH2         Maijiedai, Xinji                    13942.14102                 Q12809       CHEMBL240       HERG                                                                       Ion channel            VGIC
  TP53          Yijing, Maijiedai, Xinji            13900.81344                 P04637       CHEMBL4096      Cellular tumor antigen p53                                                 Transcription factor   Other
  ABCC8         Maijiedai                           13817.52659                 Q09428       CHEMBL2071      Sulfonylurea receptor 1                                                    Transporter            Other
  KCNJ11        Maijiedai                           13817.40799                 Q14654       CHEMBL1886      Potassium channel, inwardly rectifying, subfamily J, member 11             Ion channel            VGIC
  KCNJ5         Maijiedai                           169.079052                  P48544       CHEMBL3038488   Kir3.1/Kir3.4                                                              Ion channel            VGIC
  CACNA1B       Maijiedai                           593.6573686                 Q00975       CHEMBL4478      Voltage-gated N-type calcium channel alpha-1B subunit                      Ion channel            VGIC
  TARDBP        Kougan                              2584.201263                 Q13148       CHEMBL2362981   TAR DNA-binding protein 43                                                 Other                  Unclassified protein
  JAK2          Xuanyun                             2032.705321                 O60674       CHEMBL2971      Tyrosine-protein kinase JAK2                                               Kinase                 Protein Kinase
  TNNC1         Maijiedai                           2017.925664                 P63316       CHEMBL2095202   Troponin, cardiac muscle                                                   Other                  Other
  TNNI3         Maijiedai                           2017.925664                 P19429       CHEMBL2095202   Troponin, cardiac muscle                                                   Other                  Other
  TNNT2         Maijiedai                           2017.925664                 P45379       CHEMBL2095202   Troponin, cardiac muscle                                                   Other                  Other
  GMNN          Xiongmen                            95.88983101                 O75496       CHEMBL1293278   Geminin                                                                    Other                  Unclassified protein
  SMAD3         Maijiedai                           95.88983101                 P84022       CHEMBL1293258   Mothers against decapentaplegic homolog 3                                  Other                  Unclassified protein
  PPARG         Maijiedai, Xinji                    83.46168023                 P37231       CHEMBL235       Peroxisome proliferator-activated receptor gamma                           Transcription factor   Nuclear receptor
  GJA1          Maijiedai                           83.29977996                 P17302                       Gap junction alpha-1 protein                                               Other                  Unclassified protein
  PTPN11        Maijiedai                           83.26574007                 Q06124       CHEMBL3864      Protein-tyrosine phosphatase 2C                                            Enzyme                 Phosphatase
  LMNA          Maijiedai                           83.14071435                 P02545       CHEMBL1293235   Prelamin-A/C                                                               Other                  Unclassified protein
  TSHR          Maijiedai                           83.14071435                 P16473       CHEMBL1963      Thyroid-stimulating hormone receptor                                       GPCR                   Family A GPCR
  ATXN2         Kougan                              12.74911666                 Q99700       CHEMBL1795085   Ataxin-2                                                                   Other                  Unclassified protein
  SOD1          Kougan                              1.975815734                 P00441       CHEMBL2354      Superoxide dismutase                                                       Enzyme                 Oxidoreductase
  SDHA          Yijing, Maijiedai, Xinji, Xuanyun   1.990418899                 P31040       CHEMBL5758      Succinate dehydrogenase (ubiquinone) flavoprotein subunit, mitochondrial   Enzyme                 Oxidoreductase
  PON1          Kougan                              1.732079071                 P27169       CHEMBL3167      Serum paraoxonase/arylesterase 1                                           Enzyme                 Hydrolase
  KYNU          Maijiedai                           1.649920118                 Q16719       CHEMBL5100      Kynureninase                                                               Enzyme                 Hydrolase
  IFNG          Maijiedai                           1.695300734                 P01579       CHEMBL3286073   Interferon gamma                                                           Other                  Other
  CHRM3         Kougan                              0.769622544                 P20309       CHEMBL245       Muscarinic acetylcholine receptor M3                                       GPCR                   Family A GPCR
  SCN5A         Maijiedai, Xinji                    76.0137842                  Q14524       CHEMBL1980      Sodium channel protein type V alpha subunit                                Ion channel            VGIC
  DAO           Kougan                              1.396943488                 P14920       CHEMBL5485      D-amino-acid oxidase                                                       Enzyme                 Oxidoreductase
  CPT2          Maijiedai, Xiongmen                 1.020829585                 P23786       CHEMBL3238      Carnitine palmitoyltransferase 2                                           Enzyme                 Transferase
  CTNNB1        Xuanyun                             1.020829585                 P35222       CHEMBL5866      Catenin beta-1                                                             Other                  Unclassified protein
  NAGS          Xiongmen                            1.020829585                 Q8N159                       N-acetylglutamate synthase, mitochondrial                                  Enzyme                 Transferase
  TTR           Maijiedai                           1.001902474                 P02766       CHEMBL3194      Transthyretin                                                              Other                  Other
  COL3A1        Xuanyun                             0.45282272                  P02461       CHEMBL2364188   Collagen                                                                   Other                  Other
  SLC1A3        Xuanyun                             0.520835938                 P43003       CHEMBL3085      Excitatory amino acid transporter 1                                        Transporter            Electrochemical transporter
  HNF4A         Maijiedai                           0.386540369                 P41235       CHEMBL5398      Hepatocyte nuclear factor 4-alpha                                          Other                  Unclassified protein
  AKT1          Maijiedai                           0.26386963                  P31749       CHEMBL4282      Serine/threonine-protein kinase AKT                                        Kinase                 Protein kinase
  GAA           Maijiedai                           0.261304876                 P10253       CHEMBL2608      Lysosomal alpha-glucosidase                                                Enzyme                 Hydrolase
  LDLR          Maijiedai                           0.132692707                 P01130       CHEMBL3311      LDL receptor                                                               Other                  Membrane receptor
  EGF           Xuanyun                             0.159065607                 P01133       CHEMBL5734      Pro-epidermal growth factor                                                Other                  Unclassified protein

Pharmacodynamic Research of High-Weight Components in XSN {#s3_4}
---------------------------------------------------------

Based on our previous study, XSN is a class III anti-arrhythmic drug supported by the prolongation of the action potential of cardiac myocytes through blocking hERG channel ([@B27]; [@B40]), and it also showed class I antiarrhythmic property of blocking sodium channels ([@B41]). However, the available pharmacological research data of all the components in the 11 herbs of XSN reported and recorded in all the databases are not sufficient to correlate with the clinical antiarrhythmic efficacy and our discovery that inhibit human cardiac sodium current, Na~V~1.5 channel (encoded by gene SCN5A) with total target weight coefficient of 1.32 ([@B41]). Comparing with the effect of hERG channel (encoded by KCNH2), total target weight coefficient of hERG is 14838.89; both of them are with similar IC~50~ values generated by XSN, which can be considered as a combination of all the components. Thus, we screen the set of high-weight components with reported content in corresponding herbs on inhibiting Na~V~1.5.

Two high-weight active components: liensinine (LSN, PubChem CID: 160644) and isoliquiritigenin (ISL, PubChem CID: 638278) were detected using electrophysiological approaches. LSN is the No. 35 high-weight component, which blocked human Na~V~1.5 channel dose-dependently with an IC~50~ of 3.58 ± 0.36 μM ([**Figure 4**](#f4){ref-type="fig"}). ISL reduced peak I~Na~ concentration dependently, with a median inhibitory concentration (IC~50~) of 10.11 μM ± 1.12 μM. The positive control amiodarone (AMD) blocks Na~V~1.5 channel with IC~50~ = 5.05 ± 0.55 μM.

![**(A)** Chemical structure of liensinine (LSN) and isoliquiritigenin (ISL). **(B)** Dose--response curve of the inhibition on human Na~V~1.5 channel by amiodarone (AMD, n=5), LSN (n=6), and ISL (n=8).](fphar-10-01138-g004){#f4}

Panoramagram of the Pharmacological Mechanism of XSN {#s3_5}
----------------------------------------------------

Including the pharmacological effects of LSN and ISL, a panoramagram of the integrative pharmacological mechanism of XSN was interpreted (shown as [**Figure 5**](#f5){ref-type="fig"}). The pharmacological network consisted of 963 components, 618 targets, and 10 symptoms. This panoramagram illustrated the network pharmacological relationships among the XSN formula, herbs, components, targets, symptoms, and PHHD arrhythmia.

![Panoramagram of the pharmacological mechanism of XSN for treating PHHD arrhythmia. This panoramagram illustrated the connections among the XSN formula, herbs, components, targets, symptoms, and PHHD arrhythmia. **(A)** XSN formula and components. All the 11 herbs were shown as figures in the box with different colors, and the components of each herb were shown as small square with the same color as their source herb. **(B)** XSN target spectrum. All the targets were corresponding to the component in panel A; the 41 targets showed in the dash line box in the bottom is the overlapping target set between XSN target spectrum and PHHD-arrhythmia target spectrum. Targets were shown in different shapes according to the classifications as indicated in the keys. **(C)** Arrhythmia with PHHD Zheng and relative TCM symptoms. Ten TCM symptoms of PHHD arrhythmia were represented by large pink squares in the bottom panel.](fphar-10-01138-g005){#f5}

Pathways Involved in the Pharmacological Mechanism of XSN on Treating PHHD Arrhythmia {#s3_6}
-------------------------------------------------------------------------------------

All the 40 common targets between XSN target spectrum and PHHD-arrhythmia target spectrum were selected to carry out pathway enrichment with Reactome application in Cytoscape. 117 pathways with FDR less than 0.05 were obtained and resort by total weight coefficients ([**Figure 6**](#f6){ref-type="fig"}, [**Supplement Table 5**](#SM5){ref-type="supplementary-material"}).

![Pathway enrichment results of 40 targets of XSN on treating PHHD arrhythmia. Top 50 pathways were shown here; and all were sorted by pathway weight coefficient.](fphar-10-01138-g006){#f6}

To better understand the antiarrhythmic therapeutic efficacy of XSN, cardiac conduction pathway is calculated to hold the highest total weight coefficient in the list of resorting pathway total weight coefficient. It was shown in [**Figure 7**](#f7){ref-type="fig"} and all the components in XSN involved in regulating this pathway were marked in the figure.

![Cardiac conduction pathway. Top 1 pathway in the rank of total target weight coefficient, all the target regulated in this pathway were marked in red ([@B15]).](fphar-10-01138-g007){#f7}

Discussion {#s4}
==========

Tan-Re-Rao-Xin Zheng is named as PHHD syndrome in English. Based on the traditional Chinese Medicine theories, PHHD is defined as that heat having existed in the body for a period of time without distributing leads to the body\'s fluids being concentrated as Phlegm. The concept *Heart* in the Chinese medicine mainly refers to the circulatory system and nervous system, and they are easily to be blocked or obstructed to cause malfunction ([@B17]). This is why PHHD is classified as an "excess" syndrome; the heat and the phlegm must be cleared to treat the symptoms in circulatory system and neuronal system successfully.

Physical symptoms of PHHD are usually consist of the followings (Yongdun et al., 2005; [@B30]; [@B44]): (1) insomnia, difficulty in falling asleep and frequent dream-disturbed waking. (2) Palpitations, the heart rhythm becomes out of control, e.g., PVCs or tachycardia. However, it depends on the severity of how much the heart had been disturbed by the phlegm fire; the clinical manifestation could range from incidental PVC to frequent PVC or from normal heart rate to tachycardia. In the region of the heart, there is often a sensation of heat or discomfort and oppressed chest, feeling difficult to breath. (3) Tongue, tongue body is red, especially at the tip, which is often swollen and painful. The tongue coating is yellow and thick. There is very often a mid-line crack extending to the tip, with yellow moss on it. Hypertension---high blood pressure---is often a feature of heart phlegm fire. (4) Pulse, slippery, and rapid and overflowing which means "excess"; it often appears after the first stage of infectious disease and shows excess heat. Complexion is red; eyes are bloodshot. Some mental symptoms could also happen, like boredom or even hypomania which also depends on the severity of phlegm-heat disturbing the neural system (which is also part of the *Heart* in TCM theory). Therefore, arrhythmia with obvious clinical signs of PHHD is a particular condition that the patient suffering from phlegm-heat, and the circulation system would be mostly influenced.

XSN capsule originated from the famous compound formula Huanglian Wendan (HLWD) Decoction recorded in 150 years ago, which has the effect of removing phlegm, blood stasis, and fire toxin. Huanglian, Banxia, Fuling, Gancao, and Zhishi are from the original formula HLWD decoction; Changshan, Lianzixin, Qinghao, and Kushen were added to make XSN formula more inclined to the circulation system. Therefore, XSN was not only a combination of anti-arrhythmic monomer components, but also a complex therapeutic system to regulate biological/pathological process relative to PHHD syndrome.

The compatibility principle of the herbs in XSN also reflects another key property of Chinese herbal medicine: amount/proportion of herbs in compound formula. For a better understanding of the pharmacological mechanism of XSN, we introduced a novel parameter, *weight coefficient*, to mimic the compatible combination of all the chemical components in the 11 herbs in XSN. As mentioned in methods section, weight coefficient is the product of proportion of herbs in the compound formula, content of each component in relative herb and the predicted probability of human OB of each component. Weight coefficient is not the absolute concentration of each chemical component but a relative content among them, which means the ranked order of weight coefficient of each component can be considered as the extent how much a component involved in the pharmacological mechanism of XSN. The weight coefficient of each component reflects its molar concentration in the blood; therefore, the higher the weight coefficient, the more molecules will bind to the targets. However, the binding affinity of the component to the target remains to be tested pharmacologically.

In this study, we used network pharmacological approach to visualize the complex pharmacological mechanism of XSN on treating PHHD arrhythmia. All the data were collected from databases and books to assure the quality and reliability of all the relationships in the pharmacological network. Based on our previous study, XSN can be classified as class III antiarrhythmic drug, and with some pharmacological property of class I drug ([@B34]; [@B39]; [@B41]). The application of XSN resulted in significant morphological changes of the ECG trace of isolated rat heart featured by the suppression of the R wave amplitude. The QRS complex represents ventricular depolarization as a result of activation of Na~V~1.5. Our previous study attributed the decrease in R wave amplitude to XSN dependent inhibition of I~Na~; when whole-cell sodium currents were elicited using a depolarizing pulse protocol, it was evident that XSN inhibited I~Na~ concentration dependently and reversibly. However, the data from reported research recorded in the databases were not sufficient to support all the antiarrhythmic effect of XSN; we, therefore, carried out a small scale component screening on the target of class I antiarrhythmic drug, human Na~V~1.5 channel. Given previous collected in this paper did not provide enough weight coefficient on Na~V~1.5 channel, some unidentified high-content components should target Na~V~1.5. Thus, we screened a series of high-content components listed in [**Figure 1H**](#f1){ref-type="fig"}, to replenish the component-target information. LSN and ISL were identified as active components on Na~V~1.5 channel in the present study. Briefly speaking, the pharmacologically defined inhibition of Na~V~1.5 by the active components of the 11 herbs in XSN suggests that Lien and ISL bind to the channel in its inactivated state which reduces the I~Na~ amplitude. The total weight coefficient of Na~V~1.5 is 76.013, which is still much lower than hERG 13942.141. The reason is understandable that, based on the content of components in the mixture of raw herbs of XSN, the weight of Huanglian (334g/2,377g mixture of raw herbs) is much more than Lianzixin (42g/2,377g mixture of raw herbs) and Gancao (167g/2,377g mixture of raw herbs); meanwhile, the concentration of berberine is much higher than LSN and ISL in relative herbs (details see [**Supplement Table 1**](#SM1){ref-type="supplementary-material"}). Secondly, the experimental inhibitory effect of Na~V~1.5 by XSN was carried on directly on isolated heart or cell lines without influenced by absorption, distribution, metabolism, and excretion; the predicted oral bioavailability also lower down the weight coefficients of LSN and ISL. Technically, more active components inhibiting Na~V~1.5 were still undiscovered, and further research on XSN is still needed.

Including the pharmacological effects of LSN and ISL, we drew a panoramagram of the integrative pharmacological mechanism of XSN with 475 components targeting 617 targets. Among the 617 targets, 40 targets were relative to PHHD arrhythmia. To explain the mechanism, we carried out pathway enrichment instead of subnetwork analysis, 116 pathways were obtained, and top 50 were shown as [**Figure 6**](#f6){ref-type="fig"}.

As an antiarrhythmic drug, XSN showed multiple therapeutic effects. From the standpoint of TCM treatment, both tip and root causes can be reflected in the pathways, which can also be considered as quick-acting and long-acting mechanisms. First, ion channels play essential role in terminating abnormal electrical activity in arrhythmic heart. Based on the results from the analysis above, the mechanism on cardiac electronic activity may involve such targets: TNNI3, CACNA1S, SCN5A, KCNH2, KCNJ11, and CALM1. Na~V~1.5, Ca~V~1.2, and hERG are three key ion currents in cardiac electric conduction during depolarization and repolarization. Troponins I (encoded by TNNI3) is integral to cardiac muscle contraction, which is also used as diagnostic and prognostic indicators in the management of myocardial infarction and acute coronary syndrome. Calmodulin 1 (encoded by CALM1) mediates the regulation of plenty of enzymes, ion channels, aquaporins, and other proteins acting with calcium-binding. Secondary, as long-acting mechanism, XSN was used to treat arrhythmia caused by coronary heart disease and viral myocarditis. Protection of myocardium, such as protection of I/R injury, antithrombosis and anti-apoptotic effect should be the essential effects of XSN. Intracellular sodium accumulation is a key pathophysiological mechanism in myocardial ischaemia/reperfusion (I/R) injury. Furthermore, it is thought that, Na~v~1.5, alongside NHE and other transporters, contributes to this sodium overload that can be reduced with application of lidocaine, suggesting that inhibition of I~Na~ may attenuate I/R injury. Previous work has shown XSN is cardioprotective in I/R injury induced in isolated rat hearts. Given the effect of ISL in inhibiting Na~v~1.5, it is possible that LSN and ISL reported in the present study are responsible for some of XSN's cardioprotective actions in this way.

Besides of calcium overload, another reason of myocardium injury was caused by apoptosis of cardiomyocyte. The p53 tumor suppressor is one of the major apoptosis signaling pathways. It regulates a wide variety of genes involved in apoptosis, growth arrest, or senescence in response to genotoxic or cellular stress. The p53 can promote apoptosis through interactions with Bcl-2 family proteins in the cytoplasm. In addition, HIF1 alpha was also downregulated by the top1 component berberine ([@B28]). Berberine inhibits doxorubicin-induced cardiomyocyte apoptosis ([@B26]).

Inflammatory response is well recognized as a critical contributor for the development and complications of atherosclerosis cardiovascular disease (ASCVD), including myocardial infarction (MI), heart failure, and stroke, which involve complex interactions between multiple biological processes.

Besides of cardiovascular pathways, several diabetic pathways were also obtained. In TCM system, disease with diabetes-related symptoms is called "*Xiaoke*," which is primarily caused by deficiency of Yin with dryness and heat syndromes as the secondary cause ([@B35]). As both PHHD and *Xiaoke* partially shared the pathogenesis of heat, it is understandable to share some biological pathways in common. In type II diabetes mellitus, insulin secretion, integration of energy metabolism pathways, KCNJ11, and ABCC8 were the common targets, which may be regulated by XSN. The beta‐cell ATP‐sensitive potassium (KATP) channel is a key component of stimulus‐secretion coupling in the pancreatic beta‐cell. The channel coupled metabolism to membrane electrical events bringing about insulin secretion. The channel consists of four subunits of the inwardly rectifying potassium channel Kir6.2 and four subunits of the sulfonylurea receptor 1 (SUR1).

Beyond of these targets, several targets including fatty acid synthase (FASN), pyruvate kinase L/R (PKLR), acetyl-CoA carboxylase (ACC, alpha unit encoded by ACACA), transketolase (TKT), free fatty acid receptor 1(FFAR1), glucagon-like peptide 1 receptor (GLP1R), and so on were also regulated by XSN. These targets are involved in the bioprocess of glycolysis, fatty acid synthesis, and pentose phosphate pathway, which are key steps of glucose and lipid metabolism. Through these mechanisms, XSN may improve fatty acid storage and convert it into glycogen. Lipid metabolism disorder has been reported being related to the TCM heat syndrome ([@B26]), which also suggest XSN regulate glucose and lipid metabolism to act as removing the extra heat based on the TCM theories.

In summary, the mechanism of XSN on treating PHHD arrhythmia may act as follows: on quick-acting aspect, XSN balanced the ion current of the heart by regulating multiple ion channels to terminate cardiac arrhythmia; on the long-acting aspect, XSN protects the heart from I/R injury, inhibits the apoptosis of cardiomyocyte, and improves glucose and lipid metabolism. Part of the mechanism of XSN on treating PHHD syndrome by sharing pathways with insulin secretion or glucose and lipid metabolism also suggest the potential therapeutic effect of diabetes and diabetic cardiopathy.
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